Year None202220212020201920182017 Turning Point Therapeutics to Participate in Upcoming Investor Conferences May 26, 2022 Turning Point Therapeutics Announces Appointment of Steve Sabus as Chief Commercial Officer May 16, 2022 Turning Point Therapeutics Reports First-Quarter 2022 Financial Results, Provides Operational Updates May 10, 2022 Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With One Prior ROS1 Tyrosine Kinase Inhibitor and no Prior Chemotherapy May 10, 2022 Turning Point Therapeutics Announces Pipeline Expansion, Licensing of TPX-4589 (LM-302), A Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate for Gastrointestinal Cancers, From Lanova Medicines May 05, 2022 Turning Point Therapeutics and Zai Lab Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study Apr 28, 2022 Turning Point Therapeutics Announces Positive Topline Data by Blinded Independent Central Review for Repotrectinib Across All ROS1-Positive NSCLC Cohorts of Phase 1/2 TRIDENT-1 Study Apr 12, 2022 Turning Point Therapeutics Announces Appointment of Brian Sun, M.S., J.D., as Incoming General Counsel Mar 29, 2022 Turning Point Therapeutics Announces Achievement of Enrollment Goal for TRIDENT-1 NTRK-Positive TKI-Pretreated Advanced Solid Tumor Patients and Plans for Pre-NDA Meeting for This Patient Population Mar 21, 2022 Turning Point Therapeutics to Participate in Upcoming Investor Conferences Mar 09, 2022 Pagination Current page 1 Page 2 Next page next › Last page last »
